Scarica l'app Stockscreener
4.59
2.00%
0.09
Precedente Chiudi:
$4.50
Aprire:
$4.73
Volume 24 ore:
31,847
Relative Volume:
0.21
Capitalizzazione di mercato:
$36.18M
Reddito:
$2.34M
Utile/perdita netta:
$-30.37M
Rapporto P/E:
-1.56
EPS:
-2.9424
Flusso di cassa netto:
$-23.42M
1 W Prestazione:
+4.79%
1M Prestazione:
+4.32%
6M Prestazione:
-5.75%
1 anno Prestazione:
+9.29%
Intervallo 1D:
$4.38
$4.73
Intervallo di 1 settimana:
$4.26
$4.73
Portata 52W:
$3.62
$16.25
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Nome
Radiopharm Theranostics Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare RADX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
4.59 | 36.18M | 2.34M | -30.37M | -23.42M | -2.9424 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Borsa (RADX) Ultime notizie
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference - Yahoo Finance
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs - Yahoo Finance
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Radiopharm Theranostics (NASDAQ: RADX) faces 1.29-quarter cash runway - Stock Titan
Radiopharm Theranostics Reports Business Update - GlobeNewswire Inc.
Radiopharm Theranostics Reports Business Update - Sahm
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 - Sahm
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Radiopharm Theranostics LimitedSponsored ADR (NASDAQ:RADX) Sees Significant Growth in Short Interest - MarketBeat
Radiopharm Theranostics Moves HER2 Radiotherapy Candidate RAD202 to Higher Dose in Phase 1 Trial - TipRanks
Radiopharm Theranostics Taps Siemens for U.S. Supply of Fast-Tracked Brain Metastases Imaging Agent RAD101 - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Radiopharm Theranostics Doses First Patient in Phase 1 RAD 402 Prostate Cancer Trial - TipRanks
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study - Yahoo Finance
Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Ocugen (OCGN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart - TipRanks
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Fifth Third Bancorp (NASDAQ:FITB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Hartford Multifactor Emerging Markets ETF (NYSEARCA:ROAM) Short Interest Up 110.6% in January - Defense World
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Increase in Short Interest - Defense World
Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Expands By 112.1% - Defense World
GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update - Defense World
iShares Environmentally Aware Real Estate ETF (NASDAQ:ERET) Sees Significant Increase in Short Interest - Defense World
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Radiopharm Theranostics (NASDAQ:RADX) versus Bolt Biotherapeutics (NASDAQ:BOLT) Head-To-Head Survey - Defense World
Analysts Offer Insights on Healthcare Companies: Radiopharm Theranostics Limited Sponsored ADR (RADX) and Resmed (RMD) - The Globe and Mail
Radiopharm Theranostics (ASX:RAD) Prepares for Multiple 2026 Readouts with Firm Cash Position - Kalkine Media
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - Sahm
Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Radiopharm Theranostics (NASDAQ:RADX) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic - TipRanks
RAD Increases Ownership in Radiopharm Ventures to 87.5% - Sahm
RADX: Interim Readout Achieves 92% Concordance - Research Tree
Equities Analysts Issue Forecasts for RADX FY2026 Earnings - Defense World
RADX FY2026 EPS Reduced by Brookline Capital Management - MarketBeat
Analysts’ Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON) - The Globe and Mail
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India
Radiopharm Theranostics Ltd Adr Azioni (RADX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):